TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial Comparing Low Molecular Weight Heparin and Aspirin to Aspirin Alone in Women With Unexplained Recurrent Pregnancy Loss
Brief Summary: To compare the livebirth rate of women with recurrent pregnancy loss and autoantibodies randomized to either low molecular weight heparin plus aspirin versus aspirin alone.


Options:
A: Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Aspirin + heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: Heparin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin, Aspirin + heparin | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Aspirin + heparin
B: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Low molecular weight heparin and low dose aspirin | Arm Label: b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Intervention Type: DRUG; Name: Low molecular weight heparin and low dose aspirin; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): b
C: Arm Label: Group A(heparin group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Group A(heparin group)
D: Arm Label: ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: Klexane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane | Arm Label: Aspirin and Enoxaparine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane and ASA | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): ASA | Intervention Type: DRUG; Name: Klexane; Assigned to Arm(s): Klexane | Intervention Type: DRUG; Name: Klexane and ASA; Assigned to Arm(s): Aspirin and Enoxaparine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial Comparing Low Molecular Weight Heparin and Aspirin to Aspirin Alone in Women With Unexplained Recurrent Pregnancy Loss
Brief Summary: To compare the livebirth rate of women with recurrent pregnancy loss and autoantibodies randomized to either low molecular weight heparin plus aspirin versus aspirin alone.


Options:
A: Arm Label: Multivitamin supplement; Type: OTHER; Interventions: Dietary Supplement: Multivitamin supplement | Arm Label: Multivitamin supplement + dalteparin sodium; Type: EXPERIMENTAL; Interventions: Drug: Fragmin P Forte (dalteparin sodium) | Intervention Type: DRUG; Name: Fragmin P Forte (dalteparin sodium); Assigned to Arm(s): Multivitamin supplement + dalteparin sodium | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplement; Assigned to Arm(s): Multivitamin supplement
B: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Low molecular weight heparin and low dose aspirin | Arm Label: b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Intervention Type: DRUG; Name: Low molecular weight heparin and low dose aspirin; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): b
C: Arm Label: Standard of Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin 81 mg | Intervention Type: DRUG; Name: Aspirin 81 mg; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Standard of Care Arm
D: Arm Label: Low molecular weight heparin; Type: N/A; Interventions: Drug: low molecular weight heparin (enoxeparine) | Intervention Type: DRUG; Name: low molecular weight heparin (enoxeparine); Assigned to Arm(s): Low molecular weight heparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial Comparing Low Molecular Weight Heparin and Aspirin to Aspirin Alone in Women With Unexplained Recurrent Pregnancy Loss
Brief Summary: To compare the livebirth rate of women with recurrent pregnancy loss and autoantibodies randomized to either low molecular weight heparin plus aspirin versus aspirin alone.


Options:
A: Arm Label: Enoxaparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Warfarin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin group | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin group
B: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Experimental: Rivaroxaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Experimental: Rivaroxaban | Intervention Type: DRUG; Name: Experimental: Rivaroxaban; Assigned to Arm(s): Rivaroxaban, Warfarin
C: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Low molecular weight heparin and low dose aspirin | Arm Label: b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Intervention Type: DRUG; Name: Low molecular weight heparin and low dose aspirin; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): b
D: Arm Label: Group A(heparin group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Group A(heparin group)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial Comparing Low Molecular Weight Heparin and Aspirin to Aspirin Alone in Women With Unexplained Recurrent Pregnancy Loss
Brief Summary: To compare the livebirth rate of women with recurrent pregnancy loss and autoantibodies randomized to either low molecular weight heparin plus aspirin versus aspirin alone.


Options:
A: Arm Label: ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: Klexane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane | Arm Label: Aspirin and Enoxaparine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane and ASA | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): ASA | Intervention Type: DRUG; Name: Klexane; Assigned to Arm(s): Klexane | Intervention Type: DRUG; Name: Klexane and ASA; Assigned to Arm(s): Aspirin and Enoxaparine
B: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Low molecular weight heparin and low dose aspirin | Arm Label: b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Intervention Type: DRUG; Name: Low molecular weight heparin and low dose aspirin; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): b
C: Arm Label: enoxaparin 40 mg plus low dose aspirin; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin 40mg plus low dose aspirin | Arm Label: Heparin calcium 5,000 U twice daily plus low dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin calcium5,000 U twice daily plus low dose aspirin | Intervention Type: DRUG; Name: enoxaparin 40mg plus low dose aspirin; Assigned to Arm(s): enoxaparin 40 mg plus low dose aspirin | Intervention Type: DRUG; Name: Heparin calcium5,000 U twice daily plus low dose aspirin; Assigned to Arm(s): Heparin calcium 5,000 U twice daily plus low dose aspirin
D: Arm Label: Enoxaparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Warfarin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin group | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Retinal Structure With High Resolution OCT
Brief Summary: Comparison of different OCT instruments to assess retinal thickness, correlation to fluorescein angiography, and visual outcome after therapy with anti-VEGF therapy


Options:
A: Arm Label: 1; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 2; Type: N/A; Interventions: N/A | Arm Label: 3; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 4; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 5; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 6; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 7; Type: N/A; Interventions: Other: Examination with an OCT device | Intervention Type: OTHER; Name: Examination with an OCT device; Assigned to Arm(s): 1, 3, 4, 5, 6, 7
B: Intervention Type: DRUG; Name: pegaptanib sodium; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Intravitreal Triamcinolone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Radial Optic Neurotomy; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Placebo - Sham Intravitreal Injection; Assigned to Arm(s): N/A
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: B; Type: SHAM_COMPARATOR; Interventions: Drug: ranibizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized, Double-Blind Placebo-Controlled, Multicenter, Parallel-Group, Repeated-Dose Study of the Analgesic Efficacy & Safety of IV Acetaminophen Versus Placebo for the Treatment of Postop Pain
Brief Summary: This research study will look at the pain relieving ability and safety of using repeated doses of intravenous (into the vein \[IV\]) acetaminophen in the treatment of moderate postoperative pain after planned or elective abdominal laparoscopic surgery, such as a laparoscopic abdominal hysterectomy or laparoscopic cholecystectomy (removal of the gall bladder).


Options:
A: Arm Label: Paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol | Arm Label: Dipyrone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dipyrone | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Dipyrone; Assigned to Arm(s): Dipyrone
B: Arm Label: IV Placebo 100 ml; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo | Arm Label: IV Placebo 65 ml; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo | Arm Label: IV Acetaminophen 1 gm; Type: EXPERIMENTAL; Interventions: Drug: IV Acetaminophen | Arm Label: IV Acetaminophen 650 mg; Type: EXPERIMENTAL; Interventions: Drug: IV Acetaminophen | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): IV Placebo 100 ml | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): IV Placebo 65 ml | Intervention Type: DRUG; Name: IV Acetaminophen; Assigned to Arm(s): IV Acetaminophen 1 gm | Intervention Type: DRUG; Name: IV Acetaminophen; Assigned to Arm(s): IV Acetaminophen 650 mg
C: Arm Label: Lornoxicam; Type: EXPERIMENTAL; Interventions: Drug: Lornoxicam | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Lornoxicam; Assigned to Arm(s): Lornoxicam
D: Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Arm Label: Morphine; Type: EXPERIMENTAL; Interventions: Drug: Morphine | Arm Label: Paracetamol-morphine; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol- Morphine | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Paracetamol- Morphine; Assigned to Arm(s): Paracetamol-morphine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy
Brief Summary: A study of the efficacy and tolerability of two different ketogenic diets in children with drug resistant epilepsy; children resistant to at least two drugs randomised to reveive diet after baseline or after further 3m control period; in addition randomised to either MCT or classical ketogenic diet.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: Ketogenic diet; Assigned to Arm(s): N/A
B: Arm Label: Atkins diet group; Type: N/A; Interventions: N/A | Arm Label: Ketogenic diet group; Type: N/A; Interventions: N/A
C: Arm Label: Ketogenic diet; Type: EXPERIMENTAL; Interventions: Other: Ketogenic diet | Arm Label: Antiepileptic drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiepileptic drug therapy | Intervention Type: OTHER; Name: Ketogenic diet; Assigned to Arm(s): Ketogenic diet | Intervention Type: DRUG; Name: Antiepileptic drug therapy; Assigned to Arm(s): Antiepileptic drug therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Modified Atkins diet | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Modified Atkins diet; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison Between Internet-based Self-help Therapy and Group Therapy for Social Phobia - A Clinical Equivalence Trial Using Cognitive Behavioural Therapy (CBT)
Brief Summary: Social phobia is one of the most prevalent anxiety disorders in the western world. Cognitive behavioural therapy (CBT) is the psychological treatment that has the largest empirical support. However, the availability to CBT is very limited in Sweden due to lack of therapists with proper training. Therefore it is important to evaluate alternative forms of treatment that are more time efficient. One of these methods is Internet based self-help therapy, which has proven to be an effective treatment for social phobia.

To the investigator´s knowledge, no study has yet directly compared live-CBT to Internet therapy. The aim of the present study is to compare the effect of live CBT vs CBT delivered via the Internet. The study is considered to be an equivalence trial. 128 patients will be randomly assigned to one of the two treatment conditions. The primary outcome measure is Liebowitz Social Anxiety Scale (LSAS).


Options:
A: Arm Label: Internet-based CBT; Type: N/A; Interventions: N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CBT via the Internet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: CBT group therapy | Intervention Type: BEHAVIORAL; Name: CBT via the Internet; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: CBT group therapy; Assigned to Arm(s): 2
C: Arm Label: Internet CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based cognitive behavior therapy (CBT). | Arm Label: Group CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Group CBT | Intervention Type: BEHAVIORAL; Name: Internet-based cognitive behavior therapy (CBT).; Assigned to Arm(s): Internet CBT | Intervention Type: BEHAVIORAL; Name: Group CBT; Assigned to Arm(s): Group CBT
D: Arm Label: iSOFIE; Type: EXPERIMENTAL; Interventions: Other: iSOFIE | Arm Label: Waitlist control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: iSOFIE; Assigned to Arm(s): iSOFIE

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Parasite-based Diagnosis for Malaria in Uganda: Feasibility and Cost-Effectiveness
Brief Summary: The purpose of this study is to compare the cost-effectiveness of treating malaria based on three methods of diagnosis (rapid test, microscopy and presumptive diagnosis) among patients attending level three government health centres located in areas of low and high transmission intensities in Uganda. The study hypotheses are: in both low and high transmission areas, cost-effectiveness of malaria treatment with Artemether-Lumefantrine will be improved by the adoption of rapid diagnostic tests when compared with presumptive diagnosis or microscopy; and the difference between the cost-effectiveness of Artemether-Lumefantrine treatment following rapid diagnostic test or microscopy versus presumptive diagnosis will be greatest in low transmission areas.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Clinical algorithm and microscopy diagnosis of malaria | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Clinical algorithm and microscopy diagnosis of malaria | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Clinical algorithm and microscopy diagnosis of malaria; Assigned to Arm(s): 1, 2
B: Arm Label: Field microscopy; Type: OTHER; Interventions: Device: Field microscopy and Paracheck Pf® | Arm Label: Paracheck Pf® device; Type: OTHER; Interventions: Device: Field microscopy and Paracheck Pf® | Arm Label: Presumptive diagnostic method; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Field microscopy and Paracheck Pf®; Assigned to Arm(s): Field microscopy, Paracheck Pf® device
C: Arm Label: Observation; Type: N/A; Interventions: Drug: Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam) | Intervention Type: DRUG; Name: Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam); Assigned to Arm(s): Observation
D: Arm Label: RDT+ACT group; Type: EXPERIMENTAL; Interventions: Device: RDT, Other: Clinical Judgement as basis for treatment of malaria with ACT | Arm Label: Clinical judgement+ACT group; Type: ACTIVE_COMPARATOR; Interventions: Device: RDT, Other: Clinical Judgement as basis for treatment of malaria with ACT | Intervention Type: DEVICE; Name: RDT; Assigned to Arm(s): Clinical judgement+ACT group, RDT+ACT group | Intervention Type: OTHER; Name: Clinical Judgement as basis for treatment of malaria with ACT; Assigned to Arm(s): Clinical judgement+ACT group, RDT+ACT group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy
Brief Summary: The purpose of this study is to investigate the effect of benfotiamine supplementation in patients with diabetic nephropathy, and to determine whether it will slow down the progression to end-stage renal disease (ESRD).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Niacinamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Niacinamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benfotiamine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benfotiamine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
D: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Study Comparing the Safety & Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, & Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis
Brief Summary: To compare the efficacy of the combination of etanercept 50 mg once weekly plus methotrexate with that of methotrexate monotherapy in the treatment of rheumatoid arthritis over 88 weeks.


Options:
A: Arm Label: Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Adalimumab Tapering; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Adalimumab Withdrawal Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Adalimumab 40 mg eow Rescue Arm; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab 40 mg eow, Adalimumab 40 mg eow Rescue Arm, Adalimumab Tapering | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Adalimumab Withdrawal Arm
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Adalimumab + MTX; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: methotrexate | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab + MTX | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Adalimumab + MTX, Methotrexate

Answer: B